Scientific instruments company Waters Corporation (NYSE:WAT) reported Q1 CY2025 results topping the market’s revenue expectations , with sales up 3.9% year on year to $661.7 million. Guidance for next quarter’s revenue was better than expected at $751 million at the midpoint, 1.9% above analysts’ estimates. Its non-GAAP profit of $2.25 per share was 1.3% above analysts’ consensus estimates. Is now the time to buy Waters Corporation? Find out in our full research report. Waters Corporation (WAT) Q1 CY2025 Highlights: Revenue: $661.7 million vs analyst estimates of $654.1 million (3.9% year-on-year growth, 1.2% beat) Adjusted EPS: $2.25 vs analyst estimates of $2.22 (1.3% beat) Adjusted EBITDA: $214 million vs analyst estimates of $205.8 million (32.3% margin, 4% beat) Revenue Guidance for Q2 CY2025 is $751 million at the midpoint, above analyst estimates of $737.2 million Management slightly raised its full-year Adjusted EPS guidance to $12.90 at the midpoint Operating Margin: 22.9%, up from 21% in the same quarter last year Free Cash Flow Margin: 35.3%, down from 36.8% in the same quarter last year Organic Revenue rose 7% year on year (-9.3% in the same quarter last year) Market Capitalization: $20.73 billion "Thanks to the focus and dedication of our teams, the momentum in our business has remained strong despite a very dynamic external environment," said Dr. Udit Batra, President & CEO, Waters Corporation. Company Overview Founded in 1958 and pioneering innovations in laboratory analysis for over six decades, Waters (NYSE:WAT) develops and manufactures analytical instruments, software, and consumables for liquid chromatography, mass spectrometry, and thermal analysis used in scientific research and quality testing. Sales Growth A company’s long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Over the last five years, Waters Corporation grew its sales at a mediocre 4.8% compounded annual growth rate. This was below our standard for the healthcare sector and is a poor baseline for our analysis.Waters Corporation Quarterly Revenue We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Waters Corporation’s recent performance shows its demand has slowed as its revenue was flat over the last two years.Waters Corporation Year-On-Year Revenue Growth Waters Corporation also reports organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don’t accurately reflect its fundamentals. Over the last two years, Waters Corporation’s organic revenue was flat. Because this number aligns with its normal revenue growth, we can see the company’s core operations (not acquisitions and divestitures) drove most of its results. Story Continues Waters Corporation Organic Revenue Growth This quarter, Waters Corporation reported modest year-on-year revenue growth of 3.9% but beat Wall Street’s estimates by 1.2%. Company management is currently guiding for a 6% year-on-year increase in sales next quarter. Looking further ahead, sell-side analysts expect revenue to grow 4.5% over the next 12 months. Although this projection indicates its newer products and services will spur better top-line performance, it is still below the sector average. Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating Margin Waters Corporation has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average operating margin of 28.6%. Looking at the trend in its profitability, Waters Corporation’s operating margin decreased by 1.5 percentage points over the last five years. A silver lining is that on a two-year basis, its margin has stabilized. Still, shareholders will want to see Waters Corporation become more profitable in the future.Waters Corporation Trailing 12-Month Operating Margin (GAAP) In Q1, Waters Corporation generated an operating profit margin of 22.9%, up 1.9 percentage points year on year. This increase was a welcome development and shows it was more efficient. Earnings Per Share We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable. Waters Corporation’s EPS grew at a decent 6.7% compounded annual growth rate over the last five years, higher than its 4.8% annualized revenue growth. However, this alone doesn’t tell us much about its business quality because its operating margin didn’t expand.Waters Corporation Trailing 12-Month EPS (Non-GAAP) Diving into the nuances of Waters Corporation’s earnings can give us a better understanding of its performance. A five-year view shows that Waters Corporation has repurchased its stock, shrinking its share count by 4.7%. This tells us its EPS outperformed its revenue not because of increased operational efficiency but financial engineering, as buybacks boost per share earnings.Waters Corporation Diluted Shares Outstanding In Q1, Waters Corporation reported EPS at $2.25, up from $2.21 in the same quarter last year. This print beat analysts’ estimates by 1.3%. Over the next 12 months, Wall Street expects Waters Corporation’s full-year EPS of $11.91 to grow 11.1%. Key Takeaways from Waters Corporation’s Q1 Results It was great to see Waters Corporation’s revenue guidance for next quarter top analysts’ expectations. We were also happy its organic revenue narrowly outperformed Wall Street’s estimates. Overall, this print had some key positives. The stock remained flat at $350.53 immediately following the results. So should you invest in Waters Corporation right now? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it’s free.
Waters Corporation (NYSE:WAT) Posts Better-Than-Expected Sales In Q1, Next Quarter’s Sales Guidance is Optimistic
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...